ERBB2 and gastroesophageal junction adenocarcinoma: While PEM + TRAS + Chemo regimen demonstrates clinical efficacy for HER2‐positive gastric/GEJ adenocarcinoma, its current cost‐effectiveness in China remains suboptimal versus TRAS + Chemo regimen.